Rosario LE MOLI

Dr. Rosario LE MOLI

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DGDamiano Gullo
Damiano Gullo
ALAdele Latina
Adele Latina
FFFrancesco Frasca
Francesco Frasca
RMRosario LE MOLI
Rosario LE MOLI
GPGabriella Pellegriti
Gabriella Pellegriti
Riccardo VigneriRiccardo Vigneri
Riccardo Vigneri
Levothyroxine monotherapy is the treatment of choice for hypothyroid patients because peripheral T4 to T3 conversion is believed to account for the overall tissue requirement for thyroid hormones. However, there are indirect evidences that this may not be the case in all patients. To evaluate in a large series of athyreotic patients whether levothyroxine monotherapy can normalize serum thyroid hormones and thyroid-pituitary feedback. Retrospective study. Academic hospital. 1,811 athyreotic patients with normal TSH levels under levothyroxine monotherapy and 3,875 euthyroid controls. TSH, FT4 and FT3 concentrations by immunoassays. FT4 levels were significantly higher and FT3 levels were significantly lower (p<0.001 in both cases) in levothyroxine-treated athyreotic patients than in matched euthyroid controls. Among the levothyroxine-treated patients 15.2% had lower serum FT3 and 7.2% had higher serum FT4 compared to euthyroid controls. A wide range of FT3/FT4 ratios indicated a major heterogeneity in the peripheral T3 production capacity in different individuals. The correlation between thyroid hormones and serum TSH levels indicated an abnormal feedback mechanism in levothyroxine-treated patients. Athyreotic patients have a highly heterogeneous T3 production capacity from orally administered levothyroxine. More than 20% of these patients, despite normal TSH levels, do not maintain FT3 or FT4 values in the reference range, reflecting the inadequacy of peripheral deiodination to compensate for the absent T3 secretion. The long-term effects of chronic tissue exposure to abnormal T3/T4 ratio are unknown but a sensitive marker of target organ response to thyroid hormones (serum TSH) suggests that this condition causes an abnormal pituitary response. A more physiological treatment than levothyroxine monotherapy may be required in some hypothyroid patients.

28 April 2010 in Diabetologia
Verified
Journal Article
Closed access
PDF file
Laura SciaccaLaura Sciacca
Laura Sciacca
MCM. F. Cassarino
M. F. Cassarino
MGM. Genua
M. Genua
GPG. Pandini
G. Pandini
RMRosario LE MOLI
Rosario LE MOLI
Riccardo VigneriRiccardo Vigneri
Riccardo Vigneri

1 April 2007 in Thyroid®
Verified
Journal Article
Closed access
RMRosario LE MOLI
Rosario LE MOLI
LBLelio Baldeschi
Lelio Baldeschi
PSPeerooz Saeed
Peerooz Saeed
NRNoortje Regensburg
Noortje Regensburg
MMMaarten P. Mourits
Maarten P. Mourits
WWWilmar M. Wiersinga
Wilmar M. Wiersinga
Intravenous methylprednisolone pulses (IVMP) are more efficacious and better tolerated than oral prednisone in Graves' ophthalmopathy (GO) patients. However, acute and severe liver damage has been reported in sporadic cases during IVMP, resulting in fatal acute liver failure in four patients so far. The mechanism causing the liver damage is incompletely understood. We performed a prospective observational study in 13 patients with dysthyroid optic neuropathy (group A) and in 14 patients with moderately severe GO (group B) who were treated with high-dose (group A) or low-dose (group B) IVMP; cumulative steroid doses were 8.45 g in group A and 4.5 g in group B, and follow-up time was 24 weeks. Slight increases in serum aminotransferases (in alanine aminotransferase [ALAT] more than in aspartate aminotransferase [ASAT]) were observed, in seven patients exceeding the upper normal limit of 40 U/L. These changes were more prominent in group A than in group B as was also evident from a decrease in ASAT/ALAT ratio in group A but not in group B. Changes in serum aminotransferases occurred especially in the first 6 weeks of IVMP, becoming smaller thereafter with the decrease in steroid dosage. Pretreatment liver steatosis or diabetes were not related to liver damage, but preexistent viral hepatitis was. IVMP in GO patients causes dose-dependent liver damage by a direct toxic effect of glucocorticoids on hepatocytes. Nevertheless, IVMP seems to be pretty safe if cumulative doses exceeding 8 g are avoided and liver function is checked before and at regular intervals during pulse therapy.

16 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Antonino BELFIOREAntonino BELFIORE
Antonino BELFIORE
RRRosaria Valentina Rapicavoli
Rosaria Valentina Rapicavoli
RMRosario LE MOLI
Rosario LE MOLI
Rosamaria LappanoRosamaria Lappano
Rosamaria Lappano
Andrea MorrioneAndrea Morrione
Andrea Morrione
Veronica VellaVeronica Vella
Veronica Vella
Insulin-like growth factor 2 (IGF2) is upregulated in both childhood and adult malignancies. Its overexpression is associated with resistance to chemotherapy and worse prognosis. However, our understanding of its physiological and pathological role is lagging behind what we know about IGF1. Dysregulation of the expression and function of IGF2 receptors, insulin receptor isoform A (IR-A), insulin growth factor receptor 1 (IGF1R), and their downstream signaling effectors drive cancer initiation and progression. The involvement of IGF2 in carcinogenesis depends on its ability to link high energy intake, increase cell proliferation, and suppress apoptosis to cancer risk, and this is likely the key mechanism bridging insulin resistance to cancer. New aspects are emerging regarding the role of IGF2 in promoting cancer metastasis by promoting evasion from immune destruction. This review provides a perspective on IGF2 and an update on recent research findings. Specifically, we focus on studies providing compelling evidence that IGF2 is not only a major factor in primary tumor development, but it also plays a crucial role in cancer spread, immune evasion, and resistance to therapies. Further studies are needed in order to find new therapeutic approaches to target IGF2 action.

1 March 1998 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
MLM. Lunetta
M. Lunetta
RMRosario LE MOLI
Rosario LE MOLI
GGG. Grasso
G. Grasso
LSL. Sangiorgio
L. Sangiorgio

1 June 1999 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
RMRosario LE MOLI
Rosario LE MOLI
MWM F Wesche
M F Wesche
TBTiel‐Van Buul
Tiel‐Van Buul
WWW M Wiersinga
W M Wiersinga